^(18)F-FDG PET/CT在非小细胞肺癌预后评估中的研究进展  

Research progress of ^(18)F-FDG PET/CT in prognostic evaluation of non-small cell lung cancer

作　　者：黄丹琪 刘珈 李国栋 刘彩云 王博平 马苗苗 孙明霞 郭兰田[2] 王旭[1] HUANG Danqi;LIU Jia;LI Guodong;LIU Caiyun;WANG Boping;MA Miaomiao;SUN Mingxia;GUO Lantian;WANG Xu(Department of Nuclear Medicine,Binzhou Medical University Hospital,Binzhou 256603,Shandong,P.R.China;Department of Radiology,Binzhou Medical University Hospital,Binzhou 256603,Shandong P.R.China)

机构地区：[1]滨州医学院附属医院核医学科,山东滨州256603 [2]滨州医学院附属医院放射科,山东滨州256603

出　　处：《滨州医学院学报》2024年第2期147-151,共5页Journal of Binzhou Medical University

基　　金：国家自然科学基金(81771828)。

摘　　要：肺癌是一种进展迅速的疾病,预后不良。准确的治疗前分期和预后评估可改善非小细胞肺癌(NSCLC)的诊疗管理。^(18)F-FDG PET/CT可从分子水平准确地反映肿瘤的生物学特性,定量评估治疗反应代谢变化,在治疗前分期评估、治疗反应评估、复发性疾病检测和预后预测等方面发挥了重要作用。本文对^(18)F-FDG PET/CT在NSCLC预后评估的应用现状及研究进展进行综述。Lung cancer is a rapidly progressing disease with poor prognosis.Accurate pre-treatment staging and prognostic evaluation can improve the diagnosis and treatment management of non-small cell lung cancer(NSCLC).^(18)F-FDG PET/CT can accurately reflect the biological characteristics of tumors at the molecular level,quantitatively evaluate treatment response metabolic changes,and play an important role in pre-treatment staging evaluation,treatment response evaluation,recurrent disease detection,and prognosis prediction.This article reviews the current application status and research progress of ^(18)F-FDG PET/CT in prognosis evaluation of NSCLC.

关 键 词：非小细胞肺癌 ^(18)F-FDG PET/CT 预后 

分 类 号：R734.2[医药卫生—肿瘤]